Peter Nash

Program Coordinator at Dicerna Pharmaceuticals - Lexington, MA, US

Peter Nash's Colleagues at Dicerna Pharmaceuticals
Olivia George

Research Associate - Chemistry

Contact Olivia George

Meghan Johnson

HR Business Partner Coordinator

Contact Meghan Johnson

Lisa M.

Reception Administrative Assistant

Contact Lisa M.

Meghan Johnson

HR Business Partner Coordinator

Contact Meghan Johnson

Sana M.

Research Associate, RNAi Pharmacology Cardiometabolic

Contact Sana M.

Zhe Wang

Scientist I, Computational Biologist

Contact Zhe Wang

View All Peter Nash's Colleagues
Peter Nash's Contact Details
HQ
617-621-8097
Location
Greater Boston
Company
Dicerna Pharmaceuticals
Peter Nash's Company Details
Dicerna Pharmaceuticals logo, Dicerna Pharmaceuticals contact details

Dicerna Pharmaceuticals

Lexington, MA, US • 500 - 999 Employees
Major Drugs

Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease. Using our proprietary GalXC™ and GalXC-Plus™ RNAi technologies, we discover and develop innovative RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, our GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, we have continued to innovate and are exploring new applications of our RNAi technology with GalXC-Plus, which expands on the functionality and application of our flagship liver-targeted GalXC technology to tissues and cell types outside the liver with the potential to treat diseases across multiple therapeutic areas. Our team brings together talented experts across the fields of biology, chemistry, clinical science, medicine and more. With decades of scientific and technical experience focused on RNAi technology, we have the knowledge and experience needed to discover and develop therapies for patients with serious unmet medical needs. Between our own pipeline of core discovery and clinical candidates and those developed through collaborative relationships with some of the world's leading pharmaceutical companies, we have generated more than 20 active discovery, preclinical or clinical proprietary and collaborative programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain.

B2B Biotechnology Healthcare Pharmaceuticals Major Drugs Pharmaceutical Preparations Biotech Pharmaceuticals
Details about Dicerna Pharmaceuticals
Frequently Asked Questions about Peter Nash
Peter Nash currently works for Dicerna Pharmaceuticals.
Peter Nash's role at Dicerna Pharmaceuticals is Program Coordinator.
Peter Nash's email address is ***@dicerna.com. To view Peter Nash's full email address, please signup to ConnectPlex.
Peter Nash works in the Major Drugs industry.
Peter Nash's colleagues at Dicerna Pharmaceuticals are Olivia George, Meghan Johnson, Lisa M., Meghan Johnson, Sana M., Zhe Wang, Ashley O'Neill and others.
Peter Nash's phone number is 617-621-8097
See more information about Peter Nash